When: Tuesday 22 September | 18:00 – 19:00 (BST)Speakers: Stephen Garner and Anna GregsonWhen it was handed down, the decision by an EPO Board of Appeal to revoke Bristol-Myers Squibb’s European patent to $1.6 billion a year anti-cancer drug dasatinib created waves in the pharmaceutical industry. The patent was revoked on the grounds that the therapeutic effect of dasatinib was not made plausible in the patent application as filed. The decision was widely seen as “raising the bar” for patentability and it led pharmaceutical innovators and patent practitioners to reassess their patent filing strategies.Mathys & Squire partners Stephen Garner and Anna Gregson will review how the EPO case law has developed since revocation of the dasatinib patent in 2017. Exploring whether the Board’s decision has been widely followed, our presenters will discuss if and how innovators should adjust their filing and drafting strategy in light of the EPO’s post-dasatinib approach to plausibility.This event has now passed – click here to download a copy of the webinar recording.For queries, please email [email protected].